Abstract | PURPOSE: METHODS: We retrospectively analyzed the medical records of 55 premenopausal patients with endometriosis, who received dienogest (2 mg daily) for 6 months regarding coexistence of uterine myoma between January 2008 and June 2010. To compare these data in a case-control study, we analyzed a matched control group of 12 patients treated with leuprolide acetate (1.88 mg monthly) for 6 months having uterine myoma. RESULTS: Of the 55 patients treated with dienogest, six were associated with coexistent myoma node. Total myoma volume significantly decreased to 59.7 ± 7.0% of initial in dienogest group and 51.9 ± 5.5% in GnRHa group. Reduction rate in myoma volume was similar in both groups. CONCLUSION: Uterine myoma volume was successfully reduced by use of dienogest. Consideration of GnRHa disadvantages may lead to short- or long-term management of women with myoma who are to be managed transiently, and who wish to avoid surgical intervention, especially perimenopausal women.
|
Authors | Satoshi Ichigo, Hiroshi Takagi, Kazutoshi Matsunami, Noriko Suzuki, Atsushi Imai |
Journal | Archives of gynecology and obstetrics
(Arch Gynecol Obstet)
Vol. 284
Issue 3
Pg. 667-70
(Sep 2011)
ISSN: 1432-0711 [Electronic] Germany |
PMID | 21052701
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Gonadotropin-Releasing Hormone
- dienogest
- Nandrolone
- Leuprolide
|
Topics |
- Adult
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Case-Control Studies
- Endometriosis
(complications, drug therapy)
- Female
- Gonadotropin-Releasing Hormone
(agonists)
- Hormone Antagonists
(therapeutic use)
- Humans
- Leiomyoma
(complications, drug therapy, pathology)
- Leuprolide
(therapeutic use)
- Middle Aged
- Nandrolone
(analogs & derivatives, therapeutic use)
- Premenopause
- Retrospective Studies
- Tumor Burden
(drug effects)
- Uterine Neoplasms
(complications, drug therapy, pathology)
|